All News
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read Article
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Read Article
Predictors of RA-ILD include smoking, Dz activity, steroid use and obesity. @jeffsparks @UTSW_Rheum https://t.co/VRQc9igHWW
Dr. John Cush RheumNow ( View Tweet)
Methotrexate-induced pneumonitis (0.3% risk) is different than RA-ILD. MTX does not increase odds of RA-ILD. @jeffsparks @UTSW_Rheum https://t.co/JV1CcB0sLP
Dr. John Cush RheumNow ( View Tweet)
Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je
Links:
Dr. John Cush RheumNow ( View Tweet)
Disease activity increases the risk of future RA-ILD. For every one point increase in DAS28, theres a 35% increase risk of RA-ILD @jeffsparks @UTSW_Rheum https://t.co/P3dNDVanuL
Dr. John Cush RheumNow ( View Tweet)
MUC5B is a common genetic variant (~12%) that is strongly assoc w/ IPF, but also RA-ILD (3.1-4.7 fold risk) @jeffsparks @UTSW_Rheum https://t.co/t1Kgmj8a3x
Dr. John Cush RheumNow ( View Tweet)
Survival in RA-ILD is reduced (data from two different eras) @jeffsparks @UTSW_Rheum https://t.co/7eGgGnEgwW
Dr. John Cush RheumNow ( View Tweet)
Risk of RA-ILD is 15% (or 1 in 6) according to Mayo clinic (Olmstead county) data. @jeffsparks https://t.co/KynitLCsK7
Dr. John Cush RheumNow ( View Tweet)
#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L
Dr. John Cush RheumNow ( View Tweet)
Rheumatologist - Work-Life Survey Results
Last week, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
https://t.co/2g7oL6ltAo https://t.co/uYv7sDyO9o
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now.
https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 42 pts w/ cocaine-induced midline or systemic vasculitis; Current cocaine use common (20/23 + urine tox, including pts who prev. deniedcocaine). Found: septal perfs (75%), oronasal fistula(15%), less(27%) systemic Sxs, 56% PR3-ANCA+https://t.co/z1Z4INRSj5 https://t.co/v9ZyZD1Lrb
Links:
Dr. John Cush RheumNow ( View Tweet)
With AI and GPT-4... "The cognitive speed limit has just been lifted." - John Nosta https://t.co/mMXos8LLt6 https://t.co/imBfp37J1l
Links:
Dr. John Cush RheumNow ( View Tweet)
Spanish Society of Rheumatology (SER) study finds w/ retirement of many older (male) Rheums; there are workforce shortages. Most (59.7%) of rheums in Spain are women, the majority below age 54 yrs. https://t.co/DPs0S63Aqc https://t.co/ig4kOQWmkn
Links:
Dr. John Cush RheumNow ( View Tweet)
vit D shows no change in Fx Risk. Study of 20,326 Australians given placebo or vit D3 60K IU/mo. 46% women, age 69 yrs. W/ 5.1 yrs F/U - no effect on Fx risk (HR 0·94; 0·84–1·06). Fx in 5.6% of Vit D vs 5.9% in PBO (non-vertebral, major OP & hip Fxs https://t.co/cSbTS3xWrX https://t.co/Jipzw28Wn8
Links:
Dr. John Cush RheumNow ( View Tweet)
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?
https://t.co/XQk17P6D2f https://t.co/y5exrsicW8
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Changing the Conversation with Patients: Lupus
Join the discussion! RheumThoughts are opinion pieces from healthcare professionals.
https://t.co/NcJcCZVlbE
@drbags71 https://t.co/VfAqUkqLak
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Presents Women In Rheumatology: Contract Negotiations https://t.co/nkAu5kQj2w
Dr. John Cush RheumNow ( View Tweet)
